Oral Disease-Modifying Therapies for Multiple Sclerosis
Journal of Clinical Neurology
;
: 9-19, 2015.
Artículo
en Inglés
| WPRIM
| ID: wpr-150535
ABSTRACT
Classical multiple sclerosis (MS) treatments using first-line injectable drugs, although widely applied, remain a major concern in terms of therapeutic adherence and efficacy. New oral drugs recently approved for MS treatment represent significant advances in therapy. The oral route of administration clearly promotes patient satisfaction and increases therapeutic compliance. However, these drugs may also have safety and tolerability issues, and a thorough analysis of the risks and benefits is required. Three oral drugs have been approved by regulatory agencies for MS treatment fingolimod, teriflunomide, and dimethyl fumarate. This article reviews the mechanisms of action, safety, and efficacy of these drugs and two other drugs that have yielded positive results in phase III trials cladribine and laquinimod.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Satisfacción del Paciente
/
Cladribina
/
Medición de Riesgo
/
Adaptabilidad
/
Clorhidrato de Fingolimod
/
Dimetilfumarato
/
Esclerosis Múltiple
Tipo de estudio:
Estudio de etiología
/
Factores de riesgo
Idioma:
Inglés
Revista:
Journal of Clinical Neurology
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS